You just read:

Daiichi Sankyo Receives First Market Approval in Japan for LIXIANA® (edoxaban), a Direct Oral Factor Xa Inhibitor, for the Prevention of Venous Thromboembolism after Major Orthopedic Surgery

News provided by

Daiichi Sankyo Company, Limited

Apr 22, 2011, 08:30 ET